EACPT Geneva Congress Symposia: Drug-induced liver injury

Abstract submission is now open for the next EACPT Congress, to be held in Geneva 28-31 August 2013. The congress includes symposia, keynote lectures and peer-reviewed oral and poster communications

Symposium on drug-induced liver injury

Drug-induced liver injury (DILI) is a rare but clinically important problem. Many different drugs can cause DILI, with the pattern of injury varying between drugs. A better understanding of the genetic and environmental factors that are associated with DILI will allow the development of strategies to identify susceptible individuals prior to prescription. Current detection methods do not provide insight into injury mechanisms and do not allow prediction of clinical outcomes of liver injury. This session will focus on the molecular mechanisms that cause DILI, novel biomarkers for the diagnosis of DILI and current approaches towards classifying DILI within clinical studies.

Over 900 participants are expected to attend including health professionals, scientists, policy makers, biotechnology and pharmaceutical professionals, and others with an interest in basic and clinical pharmacology, pharmacotherapy, drug discovery and development, regulatory affairs and related areas.

See here for more on key themes of the Congress.

EACPT Geneva 2013 Congress website  www.eacpt2013.org